替罗非班治疗急性进展性缺血性脑卒中的安全性及有效性

Safety and Efficacy of Tirofiban in the Treatment of Acute Progressive Ischemic Stroke

目的:分析替罗非班治疗急性进展性缺血性脑卒中的安全性和有效性。方法:选取2019年1月—2022年12月北京京煤集团总医院神经科收治的急性进展性缺血性脑卒中患者70例作为研究对象,采取随机数字表法分为观察组(n=35)与对照组(n=35)。两组均进行脑保护治疗,对照组给予阿司匹林治疗,观察组在对照组基础上给予替罗非班治疗。比较两组美国国立卫生研究院卒中量表(NIHSS)评分、改良Rankin量表(mRS)评分、并发症发生情况、治疗效果。结果:治疗后7 d、1个月、3个月,观察组NIHSS评分低于对照组,差异有统计学意义(P<0.0001);治疗后3个月,观察组mRS评分低于对照组,差异有统计学意义(P<0.0001);观察组并发症发生率低于对照组,差异有统计学意义(P=0.0409);观察组治疗总有效率高于对照组,差异有统计学意义(P=0.0463)。结论:在脑保护治疗基础上,阿司匹林联合替罗非班治疗急性进展性缺血性脑卒中的效果显著,可改善患者神经功能的缺损程度及预后,安全性高。

Objective:To analyze the safety and efficacy of tirofiban in the treatment of acute progressive ischemic stroke.Methods:Seventy patients with acute progressive ischemic stroke admitted to Department of Neurology of Beijing Jingmei Group General Hospital from January 2019 to December 2022 were selected as the study objects,and were divided into observation group(n=35)and control group(n=35)by random number table method.Both groups received brain protection therapy.The control group was given aspirin,and the observation group was given tirofiban on the basis of the control group.The scores of the National Institutes of Health Stroke Scale(NIHSS),the Modified Rankin Scale(mRS),the incidence of complications and the treatment effect were compared between the two groups.Results:At 7 days,1 month and 3 months after treatment,the NIHSS score of observation group was lower than that of control group,and the difference was statistically significant(P<0.0001);at 3 months after treatment,the mRS score of the observation group was lower than that of the control group,and the difference was statistically significant(P<0.0001);the complication rate of the observation group was lower than that of the control group,the difference was statistically significant(P=0.0409);the total effective rate of the observation group was higher than that of the control group,and the difference was statistically significant(P=0.0463).Conclusion:On the basis of brain protection therapy,aspirin combined with tirofiban has a significant effect in the treatment of acute progressive ischemic stroke,which can improve the degree of neurological impairment and prognosis of patients with high safety.